Michael F. Powell

General Partner at Sofinnova Ventures, Inc.

Michael F. Powell

Michael F. Powell

General Partner at Sofinnova Ventures, Inc.

Overview
RelSci Relationships

2465

Number of Boards

35

Birthday

1955

Age

64

Relationships
RelSci Relationships are individuals Michael F. Powell likely has professional access to. A relationship does not necessarily indicate a personal connection.

President at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Partner at Domain Associates LLC

Relationship likelihood: Strong

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Former Chief Executive Officer & Director at Molecular Templates, Inc.

Relationship likelihood: Strong

General Partner at Canaan Management, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Dauntless Pharmaceuticals, Inc.

Relationship likelihood: Strong

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Partner & Chief Financial Officer at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Founder at Checkmate Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Ascenta Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Michael F. Powell
Potential Connections via
Relationship Science
You
Michael F. Powell
General Partner at Sofinnova Ventures, Inc.
Education
Ph.D Physical Chemistry
Class of 1981

Established in 1827, the University of Toronto has one of the strongest research and teaching faculties in North America, presenting top students at all levels with an intellectual environment unmatched in depth and breadth on any other Canadian campus. With more than 82,000* students across three campuses (St. George, Mississauga and Scarborough) and over 500,000 alumni active in every region of the world, U of T's influence is felt in every area of human endeavour.

Unknown Faculty Member, Biochemistry, Enzyme Mechanisms, Radiochemistry

The University of California, Santa Barbara (commonly referred to as UC Santa Barbara or UCSB) is a public research university and one of the 10 general campuses of the University of California system. The main campus is located on a 1,022-acre (414 ha) site near Goleta, California, United States, 8 miles (13 km) from Santa Barbara and 100 miles (160 km) northwest of Los Angeles. Tracing its roots back to 1891 as an independent teachers' college, UCSB joined the University of California system in 1944 and is the third-oldest general-education campus in the system. UCSB traces its origins back to the Anna Blake School which was founded in 1891 and offered training in home economics and industrial arts. The Anna Blake School was taken over by the state in 1909 and became the Santa Barbara State Normal School. Intense lobbying by an interest group in the City of Santa Barbara, led by Thomas Storke and Pearl Chase, persuaded the State Legislature, Governor Earl Warren, and the Regents of the University of California to move the State College over to the more research-oriented University of California system in 1944. The State College system sued to stop the takeover, but the Governor did not support the suit. A state initiative was passed, however, to stop subsequent conversions of State Colleges to University of California campuses. From 1944 to 1958 the school was known as Santa Barbara College of the University of California, before taking on its current name. When the vacated Marine Corps training station in Goleta was purchased for the rapidly-growing college, Santa Barbara City College moved into the vacated State College buildings.

Memberships
Fellow
Current

TO PROVIDE A FORUM FOR OPEN EXCHANGE AND DISSEMINATION OF SCIENTIFIC KNOWLEDGE.

Career History
General Partner
1997 - Current

Sofinnova is a clinical-stage biopharmaceutical venture capital firm focused on life science and information technology. They specializes in clinical and late preclinical investments in biopharmaceutical products and partner with entrepreneurs across all stages of company formation including securing initial funding, building successful management teams, forming impactful corporate alliances, and navigating the M&A acquisition or IPOs' process. Sofinnova invests in companies in the US and Europe that do business in the US, Israel, India, China, Japan and Europe.

General Partner
Current

Checkmate Pharmaceuticals, Inc. develops novel approaches for cancer immunotherapy. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and is headquartered in Cambridge, MA.

Investor
Current

Actelion Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of low molecular weight drugs for various medical needs. Its principal products include Tracleer, an orally available dual endothelin receptor antagonist, approved as a therapy for pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart; and Zavesca, in-licensed from Oxford GlycoSciences, an oral medication indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. The company also offers Ventavis, an inhaled synthetic analogue of prostacyclin that produces potent pulmonary vasodilation and inhibits platelet aggregation. In addition, Actelion evaluates various compounds in various phases of clinical development for treating cardiovascular, cardiopulmonary, immunological, and infectious diseases, as well as metabolic and central nervous system disorders. In addition, it has an exclusive worldwide alliance with Merck & Co, Inc. to discover, develop, and market new classes of renin inhibitors for patients suffering from cardio-renal diseases. Actelion markets Tracleer in the United States, the European Union, Japan, Canada, Australia, and Switzerland. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

Boards & Committees
Director
Current

Checkmate Pharmaceuticals, Inc. develops novel approaches for cancer immunotherapy. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and is headquartered in Cambridge, MA.

Director
Current
Director
Prior - 2012

Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA.

Chairman
Current

AIDS VACCINE ADVOCACY COALITION (AVAC) IS AN INTERNATIONAL NON-PROFIT ORGANIZATION THAT USES PUBLIC EDUCATION, POLICY ANALYSIS, ADVOCACY AND COMMUNITY MOBILIZATION TO ACCELERATE THE ETHICAL DEVELOPMENT AND GLOBAL DELIVERY OF AIDS VACCINES AND OTHER PREVENTION TECHNOLOGIES AND INTERVENTIONS.

Member, Committee for Pharmaceutical Development
Current

The University of Minnesota, Twin Cities (Minnesota, U of M, or The U) is a public research university located in Minneapolis and St. Paul, Minnesota, United States, with the Minneapolis and St. Paul campuses being approximately 5 miles (8.0 km) apart. It is the oldest and largest campus within the University of Minnesota system and has the sixth-largest main campus student body in the United States, with 51,853 students in 2012–2013. The university is broadly organized into 19 colleges and schools, and it has sister campuses in Crookston, Duluth, Morris, and Rochester.

Political Donations
$1,000
2012

Former President of United States

$2,000
2008

Former Senator from New York

Transactions
Details Hidden

Ascenta Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

SOFINNOVA VENTURE PARTNERS IX, L.P. raised money in a private placement transaction

Investments
Details Hidden

Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. The company was founded by Joel F. Martin and Michael F. Powell in May 2015 and is headquartered in San Diego, CA.

Details Hidden

Sofinnova is a clinical-stage biopharmaceutical venture capital firm focused on life science and information technology. They specializes in clinical and late preclinical investments in biopharmaceutical products and partner with entrepreneurs across all stages of company formation including securing initial funding, building successful management teams, forming impactful corporate alliances, and navigating the M&A acquisition or IPOs' process. Sofinnova invests in companies in the US and Europe that do business in the US, Israel, India, China, Japan and Europe.

Details Hidden

Mr. Keyes joined Orexigen in January 2013 as its Vice President of Finance. Prior to joining Orexigen, Mr. Keyes was at Amylin Pharmaceuticals, Inc. as Senior Director of Finance from May 2012 to January 2013 and Director, Manufacturing, Operations and Quality Finance from August 2007 to May 2012. Previously, he worked in financial and corporate strategy at Amgen, Inc. from March 2004 to July 2007, and at Baxter Healthcare Corporation from July 2002 to March 2004. Mr. Keyes holders a B.S. and M.S. in Civil Engineering from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michael F. Powell. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michael F. Powell's profile does not indicate a business or promotional relationship of any kind between RelSci and Michael F. Powell.